Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group. Zusätzlich bieten wir Ihnen in diesem Bereich Bildmaterial und Informationen zu unseren Veranstaltungen. Als Überblick unserer Forschungstätigkeiten stehen zudem unsere Annual Scientific Reports hier für Sie zum Download bereit.
18.01.2019 Prof. Loibl unter den meist zitierten Wissenschaftlern in 2018
Prof. Dr. Sibylle Loibl gehört im Jahr 2018 mit Ihrer Arbeit im Bereich der Brustkrebsforschung zu den 1% der am meisten zitierten Wissenschaftlern.
17.12.2018 Results of an interim analysis from KATHERINE trial
We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.
16.12.2018 GBG-Jahrestreffen - Anmeldung möglich
Die Anmeldung zum GBG Jahrestreffen, sowie zum AGO-Meeting 2019 in Frankfurt ist ab sofort möglich.
30.11.2018 November 2018: Exploratory analysis on obese breast cancer patients from the PANTHER trial
Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment has been published in the Annals of Oncology.
29.11.2018 GBG Research at SABCS
Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.
15.11.2018 Save the Date: AGO-Mamma 2019
Das State-of-the-Art-Meeting 2019 der AGO Organkomission Mamma wird am 16. März 2019 in Frankfurt stattfinden.
05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial
The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.
15.10.2018 GBG Research at ESMO
Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.
11.10.2018 BIG newsletter no 9 is out
We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.
27.09.2018 Paper of the month: models for pCR
A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.
11.09.2018 BCC-Breast Cancer Conference 2019 in Vienna
The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna is less than seven months away.
31.08.2018 Paper of the month: Endocrine Therapy in HEGR2 neg mBC
A review that summarized the available data on endocrine therapy for premenopausal women with HER2-negative hormone receptor-positive metastatic breast cancer (MBC) has been published in the Oncologist.
28.08.2018 GBG 79 BrainMet (BMBC): erste Daten publiziert
Die erste Analyse der BMBC-Registerstudie zur Versorgung von Patientinnen mit Hirnmetastasen wurde im European Journal of Cancer veröffentlicht.
24.08.2018 ASCO Trending: GeparNuevo
Priming the Immune System: Neoadjuvant Durvalumab Plus Chemotherapy May Be Beneficial in Triple-Negative Breast Cancer
31.07.2018 Paper of the month: BRCA1/2 Mutations and Bevacizumab
A translational research study performed with samples obtained from a cohort of patients with triple-negative breast cancer (TNBC) enrolled in the neoadjuvant GeparQuinto (GBG 44) study has been published in the Journal of Clinical Oncology.
06.07.2018 Review on Endocrine Therapy in Premenopausal HR+/HER2- Metastatic Breast Cancer
Unser Review zur Endokrine Therapie in prämenopausale Patientinnen mit Hormone Rezeptor-positivem, HER2-negativem metastasiertem Brust Krebs wurde in The Oncologist publiziert.
30.06.2018 Paper of the month: test predicts the risk of recurrence in luminal breast cancer
A translational study including samples from two randomized neoadjuvant GBG trials (GeparTrio and GeparQuattro) that aimed to evaluate a novel test (mEPclin) for predicting the risk of distance recurrence after neoadjuvant chemotherapy in patients with residual estrogen receptor (ER)-positive/HER2-negative breast cancer has been published in the Clinical Cancer Research.
04.06.2018 ASCO: GeparNuevo Presentation
GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.
31.05.2018 Paper of the month: elderly women and neoadjuvant chemotherapy
A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.
30.04.2018 Paper of the month: survival analysis of the GeparQuinto trial
We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.
